Lung cancer combo trial halted early – what we know
Disease control
Terminated
This study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in 36 adults with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combination could shrink tumors. The trial was terminated early, so re…
Phase: PHASE1, PHASE2 • Sponsor: SignalChem Lifesciences Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC